Raven Lin
CEO
Pilatus Biosciences
This startup develops first-in-class biologics that target metabolic checkpoints to reprogram the immune microenvironment in cancer treatment. Their approach aims to enhance the efficacy of therapies against challenging cancer types by improving immune system responses.
- Biotechnology
Updated 6 months ago
Funding
Funding rounds are not available yet.
Founders
Product
Features
- This startup develops first-in-class biologics that target metabolic checkpoints to reprogram the immune microenvironment in cancer treatment. Their approach aims to enhance the efficacy of therapies against challenging cancer types by improving immune system responses.